Glenmark, Strides Pharma, Cipla recall products in the US

The USFDA noted in its report that the company, a subsidiary of Mumbai-based drug firm, is recalling the affected lot due to "blister package issues." The lot was produced at Glenmark's Pithampur (Madhya Pradesh) based manufacturing facility. The USFDA stated that Glenmark initiated the Class II nationwide (US) recall on June 29 this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MvjiLxc
via IFTTT